Related references
Note: Only part of the references are listed.The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
Sanjoy K. Paul et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
Rafael Simo et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
Keiichi Torimoto et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Insights From Cardiovascular Outcome Trials with Novel Antidiabetes Agents: What Have We Learned? An Industry Perspective
Boaz Hirshberg et al.
CURRENT DIABETES REPORTS (2015)
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
Francesco Giorgino et al.
DIABETES CARE (2015)
Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials
S. R. K. Seshasai et al.
DIABETES OBESITY & METABOLISM (2015)
Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study
R. S. Weinstock et al.
DIABETES OBESITY & METABOLISM (2015)
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
Lawrence Blonde et al.
LANCET (2015)
Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
Rodney A. Hayward et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Miles Fisher et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
Tara Gurung et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2015)
A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)
Hiroshi Nomoto et al.
PLOS ONE (2015)
Cardiovascular Actions of Incretin-Based Therapies
John R. Ussher et al.
CIRCULATION RESEARCH (2014)
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
Guillermo Umpierrez et al.
DIABETES CARE (2014)
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
Carol Wysham et al.
DIABETES CARE (2014)
Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)
Z. Skrivanek et al.
DIABETES OBESITY & METABOLISM (2014)
Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
Yasuo Terauchi et al.
ENDOCRINE JOURNAL (2014)
Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
Keith C. Ferdinand et al.
HYPERTENSION (2014)
Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes
Louis Kuritzky et al.
POSTGRADUATE MEDICINE (2014)
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Michael E. Cobble et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
G. Grunberger et al.
DIABETIC MEDICINE (2012)
Cardiovascular Effects of Glucagonlike peptide-1 Agonists
Michael H. Davidson
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
Robert Ratner et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies
Steven P. Marso et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control
P. Anagnostis et al.
DIABETES OBESITY & METABOLISM (2011)
The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
G. E. Umpierrez et al.
DIABETES OBESITY & METABOLISM (2011)
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2010)
Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
Wolfgang Glaesner et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR
Guntram Schernthaner
WIENER MEDIZINISCHE WOCHENSCHRIFT (2010)
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. M. Turnbull et al.
DIABETOLOGIA (2009)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Kausik K. Ray et al.
LANCET (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association
John B. Buse et al.
DIABETES CARE (2007)
Glucagon-like peptide 1(GLP-1) in biology and pathology
JJ Meier et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Trends in cardiovascular complications of diabetes
CS Fox et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Share Paper
